West Pharmaceutical reports Q3 adjusted EPS $2.16, consensus $1.86

Reports Q3 revenue $747.4M, consensus $750.31M. “We had a solid quarter of organic net sales growth, driven by our Proprietary Products’ high-value product (HVP) and strong Contract Manufacturing components,” said Eric M. Green, President, CEO and chair of the board. “We are observing a slowdown in restocking trends by large Pharma and Generic customers, which is reflected in our revised guidance. As we look to the fourth-quarter 2023, we anticipate double-digit base, non-COVID-19-related organic sales growth, fueled by strong HVP component demand with certain customers and therapeutic categories.”